Heart Failure Treatment Has Changed — Patients Deserve to Know How
If you or someone you love has been diagnosed with heart failure, the first thing I want you to understand is this: heart failure does not mean your heart has stopped working. It means your heart is not pumping as effectively as it should. And in many cases, the right combination of heart failure medications can dramatically improve how you feel, how long you live, and whether surgery ever becomes part of the conversation.
As a cardiac surgeon, I operate on hearts for a living. But I spend a significant part of my time making sure patients are on optimal medical therapy before anyone considers an operation. Why? Because the evidence is overwhelming: guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) saves lives. The problem is that too many patients never receive it — or never receive it at the right doses.
This article is for patients and families who want to understand what modern heart failure treatment looks like, what GDMT actually involves, and how to recognize when medications alone may not be enough.
Understanding HFrEF GDMT Therapy: The Four Pillars
Heart failure with reduced ejection fraction — abbreviated HFrEF — is the type of heart failure where the heart muscle has weakened and the ejection fraction (EF) drops below 40%. A normal EF is typically 55-70%. When yours falls below that threshold, your heart is delivering less oxygen-rich blood to your body with each beat.
According to the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines, there are now four foundational medication classes that every HFrEF patient should be on, barring specific contraindications. These are not optional add-ons. They are the standard of care, and together they form what we call HFrEF GDMT therapy:
- ACE inhibitors, ARBs, or sacubitril-valsartan (ARNI): These medications reduce the strain on your heart by lowering blood pressure and blocking hormones that cause harmful remodeling. Sacubitril-valsartan (brand name Entresto) is now preferred over older ACE inhibitors based on the PARADIGM-HF trial, which showed a 20% reduction in cardiovascular death compared to enalapril.
- Beta-blockers (specifically carvedilol, metoprolol succinate, or bisoprolol): These slow your heart rate and reduce the workload on your heart. Not all beta-blockers are equal in heart failure — only these three have proven survival benefits in clinical trials.
- Mineralocorticoid receptor antagonists (MRAs) such as spironolactone or eplerenone: These block aldosterone, a hormone that drives fluid retention and scar formation in the heart. The RALES trial showed spironolactone reduced mortality by 30% in severe heart failure patients.
- SGLT2 inhibitors (dapagliflozin or empagliflozin): Originally developed for diabetes, these medications have proven to be remarkably effective in heart failure regardless of whether a patient has diabetes. The DAPA-HF and EMPEROR-Reduced trials demonstrated significant reductions in heart failure hospitalizations and cardiovascular death.
When all four classes are prescribed at target doses, the combined effect on survival is substantial. Some analyses suggest that optimal GDMT can extend life by several years compared to no treatment. Yet studies consistently show that fewer than 25% of eligible heart failure patients are on all four medication classes at target doses. That gap between what the evidence supports and what patients actually receive is one of the most important problems in cardiology today.
Why Dose Optimization Matters
Being prescribed a heart failure medication is not the same as being on the right dose. Many patients are started on low doses and never titrated up. Sometimes this is because of side effects like low blood pressure or dizziness. Sometimes it is because follow-up appointments are too infrequent. And sometimes it is simply because no one revisited the prescription.
If you are on heart failure medications but have never had a conversation with your doctor about whether your doses have been maximized, that is a conversation worth having. Dose titration is where much of the survival benefit lives.
Heart Failure Medications Beyond the Four Pillars
The four foundational classes are not the entire picture. Depending on your specific situation, your care team may also prescribe:
- Diuretics (such as furosemide or bumetanide): These help manage fluid retention and relieve symptoms like swelling and shortness of breath. They are essential for comfort but have not been shown to improve long-term survival on their own.
- Hydralazine and isosorbide dinitrate: This combination is recommended for Black patients with HFrEF who remain symptomatic despite standard GDMT, based on the A-HeFT trial which showed a 43% reduction in mortality in this population.
- Ivabradine: For patients whose heart rate remains above 70 beats per minute despite maximized beta-blocker therapy, ivabradine can provide additional heart rate lowering.
- Vericiguat: A newer option for patients with worsening heart failure who have been recently hospitalized, based on the VICTORIA trial.
The point is this: heart failure treatment is not one pill. It is a carefully layered strategy, and each layer matters. If you have been told you are on "maximum medical therapy" but you are only taking one or two of these classes, it is worth questioning whether that is truly the case.
When Heart Failure Treatment Requires More Than Medications
Here is where my perspective as a cardiac surgeon becomes directly relevant. GDMT is powerful, but it has limits. Some patients continue to deteriorate despite being on all four pillars at optimized doses. Others have structural heart problems — severe valve disease, coronary artery disease, or cardiac rhythm abnormalities — that medications alone cannot fix.
The situations where surgical or procedural intervention may need to be considered include:
- Severe coronary artery disease contributing to heart failure: If ischemia (inadequate blood flow) is driving your reduced EF, coronary artery bypass grafting (CABG) may improve heart function. The STICH trial and its long-term follow-up (STICHES) showed survival benefits from CABG in selected patients with ischemic cardiomyopathy.
- Significant mitral regurgitation: A failing heart often causes the mitral valve to leak, which creates a vicious cycle of worsening heart failure. Mitral valve repair or replacement — or in some cases, transcatheter edge-to-edge repair — can break that cycle.
- Need for a cardiac resynchronization therapy (CRT) device: Patients with a wide QRS complex on their EKG and persistent symptoms may benefit from a specialized pacemaker that coordinates the heart's contractions.
- Advanced heart failure requiring mechanical circulatory support: When the heart is failing despite everything else, a left ventricular assist device (LVAD) can be implanted to help the heart pump blood. This can serve as a bridge to heart transplant or, for some patients, as long-term destination therapy. Our heart failure condition page covers these advanced options in more detail.
- Heart transplantation: For the right candidates, transplant remains the gold standard for end-stage heart failure, with median survival exceeding 12 years.
The critical question for patients and families is: has every appropriate medication been tried and optimized before surgery is recommended? I have reviewed cases where patients were referred for LVAD implantation or transplant evaluation before ever being started on an SGLT2 inhibitor or an ARNI. That is not acceptable. Surgery should be the answer when medical therapy has been genuinely maximized — not when it has been incompletely attempted.
How to Know If Your GDMT Has Been Optimized
Here is a practical checklist you can bring to your next appointment:
- Am I on a medication from all four foundational classes (ARNI or ACE/ARB, evidence-based beta-blocker, MRA, and SGLT2 inhibitor)?
- If not, is there a documented medical reason I cannot take one of these classes?
- Are my doses at or near target levels, or is there room to increase them?
- Has my ejection fraction been rechecked after being on optimized medications for at least 3-6 months?
- Have I been evaluated for any structural issues — valve disease, coronary disease — that might need separate treatment?
You are not being difficult by asking these questions. You are being an informed patient. And in heart failure care, being informed can change your outcome.
Why a Second Opinion Matters in Heart Failure Treatment Decisions
Heart failure management sits at the intersection of cardiology, heart failure subspecialty care, and cardiac surgery. The decisions are complex. Should you have valve surgery now or optimize medications first? Is an LVAD appropriate, or are there still medical options to exhaust? Is your coronary disease severe enough to warrant bypass, or would it be better managed with stents or medications alone?
These are exactly the kinds of questions where a fresh set of eyes — especially from a cardiac surgeon who reviews the full picture — can add real clarity. I have seen cases where a cardiac surgery second opinion changed the entire treatment plan: sometimes escalating to surgery that was overdue, and other times pulling back from an operation that was premature.
If your ejection fraction is low and you are being told surgery is necessary, it is worth confirming that your medical therapy has been fully optimized. Our free cardiac surgery risk calculator can help you understand your surgical risk profile, and a full second opinion review can assess whether the timing and type of intervention make sense for your specific situation.
The Bottom Line on Heart Failure Treatment
Modern heart failure treatment is more effective than it has ever been. The four-pillar GDMT approach can improve ejection fraction, reduce hospitalizations, and extend life — but only if it is actually prescribed and properly dosed. Surgery and devices have a vital role for patients who need them, but they should complement optimized medical therapy, not replace it.
As a surgeon, I am never more satisfied than when I can tell a patient that they do not need an operation — that their medications are doing the job. And I am never more concerned than when I see a patient headed toward a major cardiac procedure without having received the medical therapy they deserved first.
If you are facing a heart failure diagnosis and have been recommended for surgery, a mechanical assist device, or transplant evaluation, a WhiteGloveMD second opinion can help you determine whether your medical therapy has been fully optimized and whether the proposed intervention is the right next step. Our reviews are conducted by a board-certified cardiac surgeon using AI-enhanced analysis of your complete medical record. Start your review today and make your next decision with confidence.